Trial
NCT00983346
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Utah
Collaborators
Millennium Pharmaceuticals, Inc.
Condition
Cancer
Intervention
Bortezomib
Why stopped
Lab Staff that was required left the institution, therefore accrual closed prematurely
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-07-11